1. All Products
  2. IPRATROPIUM bromide, 0.25mg/ml, 2ml, sol. for nebulizer
Public Pricelist

IPRATROPIUM bromide, 0.25mg/ml, 2ml, sol. for nebulizer

https://medicalguidelines.msf.org/en/node/421
https://unicat.msf.org/cat/product/66326
STD DORAIPRA5N-

Valid Article

Former Code(s): DORAZNL0311
25.1 - Antiasthmatic medicines and medicines for chronic obstructive pulmonary disease
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
R03BB01
Anatomical Therapeutic Chemical Classification according to WHOCC
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

IPRATROPIUM solution for nebulizer

Therapeutic Action

Inhaled anticholinergic bronchodilator

After inhalation, it causes rapid bronchodilation within minutes (approx. 3 min.) and lasting for 4-6 hours.

Indications

Symptoms related to bronchospasm in chronic obstructive pulmonary disease (COPD) in combination with salbutamol solution for nebuliser.

Severe acute life-threatening asthma, in association with salbutamol solution for nebuliser.

Instructions for use

Ready-to-use solution for inhalation to be given with a nebuliser and a mask.

2 different presentations:

  • 1 ml ampoule containing 0.25 mg (= 250 µg) ipratropium bromide for paediatric use (< 6 years)
  • 2 ml ampoule containing 0.50 mg (= 500 µg) for adults and children over 6 years

Method of administration:

  • Assemble the nebuliser according to the manufacturer's instructions.
  • Empty the required ipratropium solution into the nebuliser reservoir.
  • Add salbutamol solution for nebuliser.
  • Complete with 0.9% sodium chloride to obtain a total volume of 5 ml in the nebuliser reservoir.
  • Avoid eye contact with the aerosol generated by the nebuliser.
  • With pneumatic nebulisers, the flow of air or oxygen to pulse the solution will be adjusted according to the patient's condition and the manufacturer's recommendations.
  • Nebulisation should not normally exceed 10-20 minutes.
  • After nebulisation, any unused solution remaining in the nebuliser reservoir should be discarded.
  • Follow the manufacturer's instructions for use, cleaning and maintenance of the nebuliser.

Precautions for Use

Only by inhalation route. Never use nebuliser solution by parenteral route.

Do not swallow.

Storage

Below 25°C ‐ Protect from sunlight